Viking Therapeutics initiates coverage with buy rating and $94 target price
VKTX•UBS initiated coverage of Viking Therapeutics with a buy rating and a $94 target price.
Related News
EagleBank names Ces Escamilla senior director of commercial real estate strategic growth
EGBN•
National Fuel Gas publishes update to financial calendar
NFG•
Super Micro names former Western Digital executive Mark Long as new CFO
SMCI•
Oshkosh to announce third-quarter earnings
OSK•
Manulife Financial target price raised to C$69 from C$67
MFC•